INT89309

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.53
First Reported 2000
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 21
Total Number 22
Disease Relevance 12.81
Pain Relevance 7.32

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Pde4b) nucleus (Pde4b) cytoplasm (Pde4b)
Anatomy Link Frequency
cardiomyocytes 1
nose 1
neutrophil 1
hippocampus 1
Pde4b (Mus musculus)
Pain Link Frequency Relevance Heat
Morphine 30 99.80 Very High Very High Very High
narcan 8 99.76 Very High Very High Very High
antidepressant 8 99.58 Very High Very High Very High
addiction 6 99.44 Very High Very High Very High
cINOD 10 99.24 Very High Very High Very High
Hippocampus 4 99.24 Very High Very High Very High
withdrawal 6 99.08 Very High Very High Very High
fibrosis 52 98.72 Very High Very High Very High
cytokine 110 98.56 Very High Very High Very High
Inflammation 452 98.44 Very High Very High Very High
Disease Link Frequency Relevance Heat
Morphine Dependence 4 99.80 Very High Very High Very High
Pulmonary Disease 429 99.72 Very High Very High Very High
Vomiting 24 99.72 Very High Very High Very High
INFLAMMATION 485 99.12 Very High Very High Very High
Pulmonary Fibrosis 28 99.12 Very High Very High Very High
Necrosis 10 98.48 Very High Very High Very High
Cancer 15 98.12 Very High Very High Very High
Asthma 53 96.84 Very High Very High Very High
Disease 46 94.56 High High
Pneumonia 57 93.72 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We used a nose-only sub-acute smoke model to assess the effect of local inhibition of PDE4B, PDE4D and PDE7A mRNA on neutrophilic inflammation.
Negative_regulation (inhibition) of PDE4B in nose associated with inflammation
1) Confidence 0.53 Published 2009 Journal Respir Res Section Body Doc Link PMC2696437 Disease Relevance 0.67 Pain Relevance 0.24
In hippocampus, antidepressants increased PDE4A and decreased PDE4B, whereas ROL decreased PDE4A and did not change PDE4B.
Negative_regulation (decreased) of PDE4B in hippocampus associated with antidepressant and hippocampus
2) Confidence 0.41 Published 2006 Journal Brain Res. Section Abstract Doc Link 16730340 Disease Relevance 0 Pain Relevance 0.79
A selective phosphodiesterase IV inhibitor, rolipram blocks both withdrawal behavioral manifestations, and c-Fos protein expression in morphine dependent mice.
Negative_regulation (inhibitor) of phosphodiesterase IV associated with narcan, withdrawal and morphine
3) Confidence 0.41 Published 2001 Journal Behav. Brain Res. Section Title Doc Link 11163637 Disease Relevance 0.09 Pain Relevance 0.92
At lower doses where only PDE4B mRNA inhibition was measured, no reduction in neutrophil recruitment was observed (see Figures 4A and 5A).
Negative_regulation (inhibition) of PDE4B in neutrophil
4) Confidence 0.39 Published 2009 Journal Respir Res Section Body Doc Link PMC2696437 Disease Relevance 0.32 Pain Relevance 0.13
This provides evidence that PDE4B and 4D mRNA inhibition is sequence-specific and consistent with an antisense mechanism of action.
Negative_regulation (inhibition) of PDE4B
5) Confidence 0.39 Published 2009 Journal Respir Res Section Body Doc Link PMC2696437 Disease Relevance 0.31 Pain Relevance 0.08
For example, as systemic PDE4D inhibition appears to be responsible for the emetic effect [33], PDE4B-specific inhibitors might provide better therapeutic ratios.
Negative_regulation (inhibitors) of PDE4B-specific associated with vomiting
6) Confidence 0.38 Published 2009 Journal Respir Res Section Body Doc Link PMC2696437 Disease Relevance 0.73 Pain Relevance 0.18
In NHBE cells, high levels of PDE4B, 4D and 7A mRNA inhibition were correlated with reduced functional activity, as illustrated by dose-dependent inhibition of IL-8 and MCP-1 secretion.
Negative_regulation (inhibition) of PDE4B
7) Confidence 0.38 Published 2009 Journal Respir Res Section Body Doc Link PMC2696437 Disease Relevance 0.49 Pain Relevance 0.17
Total RNA was extracted from NHBE cells using the RNeasy mini kit (Qiagen); cDNA was prepared with SuperScript™ II Reverse Transcriptase (Invitrogen) and combined d(T)18 oligos (Biocorp) and PDE4B specific primers (TIB MOLBIOL).
Negative_regulation (prepared) of PDE4B
8) Confidence 0.38 Published 2009 Journal Respir Res Section Body Doc Link PMC2696437 Disease Relevance 0.17 Pain Relevance 0.07
The effects of rolipram, a selective inhibitor of phosphodiesterase 4, on the hyperlocomotion induced by several abused drugs (methamphetamine, morphine and phencyclidine) and a dopamine D1-receptor agonist (SKF81297; (+/-)-6-chloro-7,8-dihydroxy-1-phenyl-2,3 ,4,5-tetrahydro-1H-3-benzazepin hydrobromide) in mice were investigated.
Spec (investigated) Negative_regulation (inhibitor) of phosphodiesterase 4 associated with dopamine, agonist and morphine
9) Confidence 0.30 Published 2000 Journal Jpn. J. Pharmacol. Section Abstract Doc Link 10928323 Disease Relevance 0 Pain Relevance 0.33
We investigated the effect of rolipram, a selective phosphodiesterase IV inhibitor, on morphine dependence in mice.
Negative_regulation (inhibitor) of phosphodiesterase IV associated with addiction and morphine
10) Confidence 0.30 Published 2001 Journal Behav. Brain Res. Section Abstract Doc Link 11163637 Disease Relevance 0.10 Pain Relevance 0.65
1AR IP, cardiomyocytes deficient in PDE4A, PDE4B, and PDE4D were subjected to pull-down experiments.
Negative_regulation (deficient) of PDE4B in cardiomyocytes
11) Confidence 0.28 Published 2008 Journal EMBO J Section Body Doc Link PMC2196435 Disease Relevance 0 Pain Relevance 0
Effects of rolipram, a selective inhibitor of phosphodiesterase 4, on hyperlocomotion induced by several abused drugs in mice.
Negative_regulation (inhibitor) of phosphodiesterase 4
12) Confidence 0.22 Published 2000 Journal Jpn. J. Pharmacol. Section Title Doc Link 10928323 Disease Relevance 0 Pain Relevance 0.52
Therefore, PDE4 subtype inhibitors eg, PDE4B for treatment of COPD is being studied by Plexxikon.


Negative_regulation (inhibitors) of PDE4B associated with pulmonary disease
13) Confidence 0.18 Published 2007 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2695202 Disease Relevance 0.81 Pain Relevance 0.18
, CXCL8, and CCL2, and inhibitors of signal transduction proteins including phosphodiesterase 4, MAPK p38, Pl-3k, and NF?
Negative_regulation (inhibitors) of phosphodiesterase 4
14) Confidence 0.15 Published 2007 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Abstract Doc Link PMC2695202 Disease Relevance 1.04 Pain Relevance 0.31
Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice

Background

Negative_regulation (inhibition) of phosphodiesterase 4 associated with fibrosis and pulmonary fibrosis
15) Confidence 0.06 Published 2010 Journal BMC Pulm Med Section Title Doc Link PMC2881047 Disease Relevance 1.18 Pain Relevance 0.58
Phosphodiesterase 4 (PDE4) inhibitors are key
Negative_regulation (inhibitors) of Phosphodiesterase 4
16) Confidence 0.05 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC2233982 Disease Relevance 1.67 Pain Relevance 0.42
Several broad-spectrum anti-inflammatory drugs are also in development, and include inhibitors of phosphodiesterase-4, p38 mitogen-activated protein kinase and nuclear factor-kappaB.
Negative_regulation (inhibitors) of phosphodiesterase-4 associated with inflammation and cinod
17) Confidence 0.02 Published 2004 Journal Curr Opin Pharmacol Section Abstract Doc Link 15140418 Disease Relevance 0.96 Pain Relevance 0.27
Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies.
Negative_regulation (inhibitors) of Phosphodiesterase 4 associated with asthma
18) Confidence 0.01 Published 2000 Journal Eur J Med Chem Section Title Doc Link 10889326 Disease Relevance 0.23 Pain Relevance 0.18
Broad spectrum anti-inflammatory drugs are now in phase III development for COPD, and include phosphodiesterase-4 inhibitors.
Negative_regulation (inhibitors) of phosphodiesterase-4 associated with pulmonary disease, inflammation and cinod
19) Confidence 0.01 Published 2005 Journal Eur. Respir. J. Section Abstract Doc Link 15929966 Disease Relevance 1.33 Pain Relevance 0.52
Broad-range anti-inflammatory drugs are now in phase III development for COPD; they include inhibitors of phosphodiesterase 4.
Negative_regulation (inhibitors) of phosphodiesterase 4 associated with pulmonary disease, inflammation and cinod
20) Confidence 0.01 Published 2004 Journal Lancet Section Abstract Doc Link 15364192 Disease Relevance 1.10 Pain Relevance 0.34

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox